Only one cattle pneumonia vaccine in Ireland utilizes IRP technology. This technology was developed and patented by the manufacturers of Bovilis® Bovipast®RSP to allow the vaccine protect against multiple strains of Mannheimia (Pasteurella) haemolytica. Bovilis Bovipast RSP is the only cattle vaccine licensed to protect against Mannheimia (Pasteurella) haemolytica serotypes A1 and A6. Protection against both strains is vitally important and is unique to Bovilis Bovipast RSP. Do not underestimate the importance of A6 as it has been found in 63% of Mannheimia (Pasteurella) haemolytica infections in young beef animals!1
So how does IRP technology work?
1. Iron is needed for Mannheimia (Pasteurella) haemolytica to multiply
2. When Mannheimia (Pasteurella) haemolytica reach the lungs of the animal, Iron Regulated Proteins (IRPs) on their surface absorb iron
3. If cattle are vaccinated with Bovipast RSP before Mannheimia (Pasteurella) haemolytica reach the lungs, antibodies are produced against IRPs
4. These antibodies attach to the IRPs on the surface of Mannheimia (Pasteurella) haemolytica
5. These antibodies reduce the ability of the bacteria to absorb iron
6. This results in the failure of the Mannheimia (Pasteurella) haemolytica to multiply, thereby reducing clinical signs of pneumonia (fever, depression etc.)
Outbreaks of Bovine Respiratory Disease (BRD) continue to be a cause of significant economic loss and hardship for all types of Irish production systems. Good animal husbandry and farm management practices, including a comprehensive herd vaccination scheme, remain the best strategies to defend against a BRD outbreak.
- Timsit, E et al. Transmission dynamics of Mannheimia haemolytica in newly-received beef bulls at fattening operations. Veterinary Microbiology 161 (2013) 295–304.